The stock of Coherus Biosciences Inc (CHRS) has seen a -15.48% decrease in the past week, with a -24.79% drop in the past month, and a -40.83% decrease in the past quarter. The volatility ratio for the week is 9.56%, and the volatility levels for the past 30 days are at 9.44% for CHRS. The simple moving average for the past 20 days is -14.23% for CHRS’s stock, with a -30.80% simple moving average for the past 200 days.
Is It Worth Investing in Coherus Biosciences Inc (NASDAQ: CHRS) Right Now?
Coherus Biosciences Inc (NASDAQ: CHRS) has a higher price-to-earnings ratio of 5.09x compared to its average ratio, The 36-month beta value for CHRS is at 0.96. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CHRS is 111.28M, and currently, shorts hold a 27.65% of that float. The average trading volume for CHRS on March 19, 2025 was 2.03M shares.
CHRS) stock’s latest price update
The stock of Coherus Biosciences Inc (NASDAQ: CHRS) has decreased by -3.08 when compared to last closing price of 0.92.Despite this, the company has seen a loss of -15.48% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-10 that Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers – Head of IR Denny Lanfear – CEO Paul Reider – CCO Sameer Goregaoker – SVP, Immuno-Oncology Marketing Theresa LaVallee – CDO Rosh Dias – CMO Bryan McMichael – CFO Conference Call Participants Srikripa Devarakonda – Truist Securities Yigal Nochomovitz – Citigroup Colleen Kusy – Baird Michael Nedelcovych – TD Cowen Brian Cheng – JPMorgan Douglas Tsao – H.C. Wainwright Operator Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call.
Analysts’ Opinion of CHRS
Many brokerage firms have already submitted their reports for CHRS stocks, with UBS repeating the rating for CHRS by listing it as a “Neutral.” The predicted price for CHRS in the upcoming period, according to UBS is $1.50 based on the research report published on August 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see CHRS reach a price target of $11. The rating they have provided for CHRS stocks is “Outperform” according to the report published on November 17th, 2023.
CHRS Trading at -25.36% from the 50-Day Moving Average
After a stumble in the market that brought CHRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.38% of loss for the given period.
Volatility was left at 9.44%, however, over the last 30 days, the volatility rate increased by 9.56%, as shares sank -20.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.61% lower at present.
During the last 5 trading sessions, CHRS fell by -15.48%, which changed the moving average for the period of 200-days by -51.77% in comparison to the 20-day moving average, which settled at $1.0344. In addition, Coherus Biosciences Inc saw -35.69% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CHRS
Current profitability levels for the company are sitting at:
- -0.39 for the present operating margin
- 0.68 for the gross margin
The net margin for Coherus Biosciences Inc stands at 0.11. The total capital return value is set at -0.23.
Currently, EBITDA for the company is -111.67 million with net debt to EBITDA at 1.52. When we switch over and look at the enterprise to sales, we see a ratio of -0.09. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.06.
Conclusion
In conclusion, Coherus Biosciences Inc (CHRS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
